New pill shows promise for thalassemia patients in early trial
NCT ID NCT03692052
First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 34 times
Summary
This study tested a drug called AG-348 in 20 adults with a type of thalassemia that doesn't require regular blood transfusions. The goal was to see if the drug could safely raise hemoglobin levels, which carry oxygen in the blood. Participants took the pill twice daily for up to 24 weeks, with some continuing for up to 10 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Β -THALASSEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Imperial College Healthcare NHS Trust (Hammersmith Hospital)
London, W12 0HS, United Kingdom
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
UCSF Benioff Children's Hospital Oakland
Oakland, California, 94609, United States
-
University Health Network (Toronto General Hospital)
Toronto, Ontario, M5G 2C4, Canada
Conditions
Explore the condition pages connected to this study.